Novo Nordisk Adjusts Wegovy Sales Projections Due to Compounding Pharmacies

July 30, 2025 - 00:53

Novo Nordisk has announced a significant reduction in its sales forecasts for Wegovy, its popular obesity treatment, citing the impact of compounding pharmacies. These pharmacies are producing versions of Wegovy that closely mimic the original formulation, which has created a competitive market that undermines the drug's sales potential.

The company has expressed concern over the growing trend of compounding pharmacies creating these alternatives, effectively diluting the market for its branded product. In response, Novo Nordisk is taking steps to combat this issue, aiming to protect its intellectual property and maintain the integrity of its drug offerings.

The rise of compounded medications has raised questions about safety and efficacy, as these versions may not undergo the same rigorous testing and regulatory oversight as the original. As the company navigates this challenge, it remains focused on ensuring that patients receive safe and effective treatment options. The future of Wegovy's market presence hangs in the balance as Novo Nordisk works to address these compounding concerns.